Patents by Inventor Christopher L. Rinsch

Christopher L. Rinsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250228816
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Application
    Filed: April 4, 2025
    Publication date: July 17, 2025
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Publication number: 20250228817
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Application
    Filed: April 4, 2025
    Publication date: July 17, 2025
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 12358884
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: July 15, 2025
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Patent number: 12351567
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: July 8, 2025
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Publication number: 20250213524
    Abstract: The invention provides a compound of formula (I), or salt thereof, wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; for use in a method of enhancing or improving fertility in a male or female subject, for example, a human male subject. The invention also provides a method of enhancing or improving fertility in a subject (for example a male subject) comprising administering a compound of formula (I) to the subject, and compositions that find use in such methods.
    Type: Application
    Filed: December 20, 2024
    Publication date: July 3, 2025
    Inventors: Christopher L. Rinsch, Anurag Singh, Davide D'Amico
  • Patent number: 12310943
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: May 27, 2025
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Patent number: 12297182
    Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.
    Type: Grant
    Filed: January 19, 2024
    Date of Patent: May 13, 2025
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
  • Publication number: 20250049750
    Abstract: Disclosed are aqueous formulations comprising urolithins particularly water-based formulations comprising urolithins and maltodextrin. Also disclosed are compositions for admixture with water, methods for the preparation of such aqueous formulations, and to the uses of such formulations for both the treatment of diseases, disorders and conditions, for example, diseases disorders or conditions characterized by inadequate mitochondrial function and for administration to generally healthy individuals for example, for improving health and improving muscle function and performance.
    Type: Application
    Filed: August 9, 2024
    Publication date: February 13, 2025
    Inventors: Christopher L. Rinsch, Anurag Singh
  • Patent number: 12220424
    Abstract: A composition comprising: a) nicotinamide riboside and b) a urolithin which is a compound of formula (I) or a salt thereof: wherein: A, B, C and D are each independently selected from H and OH; W, X and Y are each independently selected from H and OH; and Z is selected from H and OH. The compositions are useful as medicaments, for example for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases and as dietary supplements, functional foods and beverages, and specialised nutrition or medical foods.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: February 11, 2025
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch
  • Publication number: 20240366558
    Abstract: The invention provides methods useful for treating post-viral illness, including long COVID-19, in a subject afflicted therewith comprising administering to the subject an urolithin.
    Type: Application
    Filed: August 30, 2022
    Publication date: November 7, 2024
    Inventors: Christopher L. Rinsch, Anurag Singh, Davide D'Amico
  • Patent number: 12109190
    Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 8, 2024
    Assignee: Amazentis SA
    Inventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
  • Patent number: 12036205
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: July 16, 2024
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Patent number: 12030863
    Abstract: The invention provides compounds of formula (I) or salts thereof: wherein: A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR1; each R1 being independently H or C(?O)R2, and at least one R1 group being C(?O)R2; where each R2 is selected from: CHR3NHR4, where R4 is H and R3 is a group selected from CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-3-(1H-indole), CH2CH2SCH3, CH2OH, CHOHCH3, CH2SH, CH2SeH and CH2PhpOH, wherein said R3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C4 alkyl; or R3 and R4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C3 alkyl, wherein RA is C1-C4 alkyl optionally substituted with one or more halogen, cyano or nitro groups.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: July 9, 2024
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, Rune Andreas Ringom
  • Publication number: 20240158364
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhen, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Publication number: 20240158365
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Publication number: 20240158363
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Publication number: 20240156777
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Publication number: 20240150310
    Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 9, 2024
    Inventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
  • Publication number: 20240148690
    Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 9, 2024
    Inventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
  • Publication number: 20240139149
    Abstract: Disclosed are methods for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, or cancer. Also disclosed is a method of enhancing cancer immunotherapy.
    Type: Application
    Filed: July 26, 2023
    Publication date: May 2, 2024
    Inventors: Penelope Andreux, Klaus Andreas Dugi, Christopher L. Rinsch, Florian Greten, Dominic Denk